期刊
ACS INFECTIOUS DISEASES
卷 7, 期 5, 页码 1032-1043出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.0c00278
关键词
schistosomiasis; Schistosoma mansoni; pyrido [1, 2-a]benzimidazole; antischistosomal lead; antischistosomal activity; 1-phenylethanamine
资金
- University of Cape Town
- South African Research Chairs Initiative of the Department of Science and Innovation
- Swiss National Science Foundation [320030_175585/1]
Praziquantel is currently the main drug for treating schistosomiasis, but there is a need for new antischistosomal drugs. The novel antischistosomal PBIs show potential efficacy and good hepatic microsomal stability, but exhibit some toxicity in vivo.
Praziquantel is the only widely available drug to treat schistosomiasis. With very few candidates currently in the drug development pipeline, there is an urgent need to discover and develop novel antischistosomal drugs. In this regard, the pyrido[1,2-a]benzimidazole (PBI) scaffold has emerged as a promising chemotype in hit-to-lead efforts. Here, we report a novel series of antischistosomal PBIs with potent in vitro activity (IC50 values of 0.08-1.43 mu M) against Schistosoma mansoni newly transformed schistosomula and adult worms. Moreover, the current PBIs demonstrated good hepatic microsomal stability (>70% of drug remaining after 30 min) and were nontoxic to the Chinese hamster ovarian and human liver HepG2 cells, though toxicity (selectivity index, SI < 10) against the rat L6 myoblast cell line was observed. The compounds showed a small therapeutic window but were efficacious in vivo, exhibiting moderate to high worm burden reductions of 35.8-89.6% in S. mansoni-infected mice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据